UNIVACFLU

Universal Flu Vaccine

Coordinatore	GOETEBORGS UNIVERSITET    more  Organization address address: VASAPARKEN city: GOETEBORG postcode: 405 30 contact info Titolo: Dr. Nome: Ellen Cognome: Rydberg Email: send email Telefono: +46 31 786 6470 Fax: +46 31 786 4355
Nazionalità Coordinatore	Sweden [SE]
Totale costo	4˙116˙701 €
EC contributo	4˙116˙701 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2013-ITN
Funding Scheme	MC-ITN
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-11-01   -   2017-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	GOETEBORGS UNIVERSITET  Organization address address: VASAPARKEN city: GOETEBORG postcode: 405 30 contact info Titolo: Dr. Nome: Ellen Cognome: Rydberg Email: send email Telefono: +46 31 786 6470 Fax: +46 31 786 4355	SE (GOETEBORG)	coordinator	1˙159˙857.90
2	KING'S COLLEGE LONDON  Organization address address: Strand city: LONDON postcode: WC2R 2LS contact info Titolo: Mr. Nome: Paul Cognome: Labbett Email: send email Telefono: +44 2078488184 Fax: +44 2078488187	UK (LONDON)	participant	831˙765.44
3	VIB  Organization address address: Rijvisschestraat 120 city: ZWIJNAARDE - GENT postcode: 9052 contact info Titolo: Mr. Nome: Rik Cognome: Audenaert Email: send email Telefono: +32 9 244 66 11	BE (ZWIJNAARDE - GENT)	participant	589˙160.00
4	MIVAC DEVELOPMENT AB  Organization address address: ARVID WALLGRENS BACKE 20 city: GOTEBORG postcode: 413 46 contact info Titolo: Mrs. Nome: Elisabeth Cognome: Litsmark Nordenstam Email: send email Telefono: +46 705 508617 Fax: +46 31 7866330	SE (GOTEBORG)	participant	350˙966.88
5	UNIVERSITE DE LILLE II - DROIT ET SANTE  Organization address address: RUE PAUL DUEZ 42 city: Lille postcode: 59800 contact info Titolo: Dr. Nome: Marie Cognome: Gompel Email: send email Telefono: +33 320965215	FR (Lille)	participant	345˙664.90
6	ISTITUTO EUROPEO DI ONCOLOGIA SRL  Organization address address: Via Filodrammatici 10 city: MILANO postcode: 20121 contact info Titolo: Ms. Nome: Ilaria Cognome: Foti Email: send email Telefono: 390257000000 Fax: 390257000000	IT (MILANO)	participant	325˙517.28
7	UNIVERSITAETSKLINIKUM FREIBURG  Organization address address: HUGSTETTER STRASSE 49 city: FREIBURG postcode: 79106 contact info Titolo: Mr. Nome: Juergen Cognome: Dreyer Email: send email Telefono: +49 761 27020810 Fax: +49 76127018890	DE (FREIBURG)	participant	300˙491.84
8	RETROSCREEN VIROLOGY LTD  Organization address address: NEW ROAD QUEEN MARY BIOENTERPRISE INNOVATION CENTRE 42 city: LONDON postcode: E1 2AX contact info Titolo: Mr. Nome: Paul Cognome: Cooper Email: send email Telefono: +44 2077561331 Fax: +44 203070086	UK (LONDON)	participant	213˙276.80

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Currently licensed influenza vaccines promote an effective antibody response, but only against influenza virus strains that antigenically match the vaccine composition. Little protection is induced by these vaccines against antigenically drifted strains such as those emerging from an avian or swine reservoir. Hence there is a great need to develop broadly cross-reactive flu-vaccines. The aim is to establish a European training platform to integrate young researchers in a highly innovative interdisciplinary strategy to develop mucosal flu-vaccines. The Universal Influenza Vaccine (UNIFLUVAC) network is aimed at harnessing the expertise of the most accomplished vaccine researchers, developers and regulators in Europe in a timely and multidisciplinary training approach unparalleled in any single EU country. The training program is extensive and builds on the integrated added values of complementing expertise and the full access to state-of-the- art technologies and excellent training environments. This unique consortium has 2 SMEs as fully committed members to guarantee strong intersectoral cooperation between industry and academia.

The partners represent 6 leading universities in 6 different member countries, securing excellent presence in Europe. The structure of UNIFLUVAC is specifically adapted to operate over the whole range of specialized expertise needed. Specifically, UNIFLUVAC provides vaccine antigen identification and expression, adjuvant design and formulation, testing in state-of-the-art preclinical animal models and finally clinical safety, immunogenicity and efficacy trials in excellent and for Europe unique medical centres. This is the strength and appeal of the UNIFLUVAC proposal. It will also establish a long-term European network based on a new cohort of young professionals with excellent employability and career opportunities in academic, clinical or industrial settings. UNIFLUVAC will have a major impact on human health in Europe and globally.'